[go: up one dir, main page]

SG11202003662XA - Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors - Google Patents

Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors

Info

Publication number
SG11202003662XA
SG11202003662XA SG11202003662XA SG11202003662XA SG11202003662XA SG 11202003662X A SG11202003662X A SG 11202003662XA SG 11202003662X A SG11202003662X A SG 11202003662XA SG 11202003662X A SG11202003662X A SG 11202003662XA SG 11202003662X A SG11202003662X A SG 11202003662XA
Authority
SG
Singapore
Prior art keywords
pyrrolo
pyrimidine
inhibitors
dione derivatives
novel pyrazolo
Prior art date
Application number
SG11202003662XA
Inventor
Marcus Koppitz
Holger Siebeneicher
Nico Bräuer
Elisabeth Pook
Andrea Rotgeri
Roland Neuhaus
Oliver Fischer
Jens Nagel
Adam Davenport
James Carr
Robert Townsend
Ursinyova Nina Connelly
Shelley Parrott
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of SG11202003662XA publication Critical patent/SG11202003662XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202003662XA 2017-10-27 2018-10-18 Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors SG11202003662XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27
PCT/EP2018/078567 WO2019081343A1 (en) 2017-10-27 2018-10-18 Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
SG11202003662XA true SG11202003662XA (en) 2020-05-28

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003662XA SG11202003662XA (en) 2017-10-27 2018-10-18 Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors

Country Status (26)

Country Link
US (1) US11319324B2 (en)
EP (1) EP3700907B1 (en)
JP (1) JP7250011B2 (en)
KR (1) KR20200078567A (en)
CN (1) CN111527090B (en)
AU (1) AU2018354777A1 (en)
BR (1) BR112020008122B1 (en)
CA (1) CA3080249A1 (en)
CL (1) CL2020001107A1 (en)
CO (1) CO2020005065A2 (en)
CR (1) CR20200174A (en)
CU (1) CU20200038A7 (en)
DK (1) DK3700907T3 (en)
DO (1) DOP2020000100A (en)
EA (1) EA202091003A1 (en)
EC (1) ECSP20023626A (en)
ES (1) ES2914377T3 (en)
IL (1) IL274036A (en)
JO (1) JOP20200100A1 (en)
MA (1) MA50439A (en)
MX (1) MX2020004981A (en)
NI (1) NI202000031A (en)
PE (1) PE20200932A1 (en)
PH (1) PH12020550494A1 (en)
SG (1) SG11202003662XA (en)
WO (1) WO2019081343A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (en) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 Nitrogen-containing cyclic derivative inhibitor, preparation method and application thereof
WO2021115225A1 (en) * 2019-12-10 2021-06-17 上海翰森生物医药科技有限公司 Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
CN117412974A (en) * 2021-06-09 2024-01-16 上海翰森生物医药科技有限公司 Salt and crystal form containing pyrazole polycyclic derivative as well as preparation method and application thereof
US20240351992A1 (en) * 2021-08-17 2024-10-24 Glaxosmithkline Intellectual Property (No.3) Limited Preparation of p2x3 antagonist
TW202509037A (en) * 2023-05-17 2025-03-01 香港商英矽智能科技知識産權有限公司 Spiro derivatives as wrn inhibitors
US20250230168A1 (en) * 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869789A (en) 1988-07-21 1990-02-19 Upjohn Company, The Pyrazolo-pyrrolo-pyrimidine-diones
CA2206080A1 (en) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesic composition_of pryazolo{1,5-a}pyrimidine derivatives
KR20020050257A (en) 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Prevention of Plaque Rupture by ACAT Inhibitors
AR061625A1 (en) 2006-06-23 2008-09-10 Incyte Corp DERIVATIVES OF PURINONA AS AGONISTS OF HM74A
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2742046A1 (en) * 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
WO2013185124A1 (en) 2012-06-08 2013-12-12 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
ES2638179T3 (en) * 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CR20200174A (en) 2020-06-26
MA50439A (en) 2021-05-19
IL274036A (en) 2020-06-30
DOP2020000100A (en) 2020-09-15
CU20200038A7 (en) 2021-03-11
CA3080249A1 (en) 2019-05-02
PE20200932A1 (en) 2020-09-17
EP3700907A1 (en) 2020-09-02
PH12020550494A1 (en) 2021-01-11
NI202000031A (en) 2020-08-28
US11319324B2 (en) 2022-05-03
US20210317128A1 (en) 2021-10-14
MX2020004981A (en) 2020-08-24
EA202091003A1 (en) 2020-09-11
CN111527090A (en) 2020-08-11
DK3700907T3 (en) 2022-05-30
ECSP20023626A (en) 2020-06-30
AU2018354777A1 (en) 2020-04-16
CO2020005065A2 (en) 2020-05-29
KR20200078567A (en) 2020-07-01
WO2019081343A1 (en) 2019-05-02
EP3700907B1 (en) 2022-03-09
JOP20200100A1 (en) 2020-05-06
BR112020008122A2 (en) 2020-11-03
CN111527090B (en) 2023-05-26
JP7250011B2 (en) 2023-03-31
ES2914377T3 (en) 2022-06-10
CL2020001107A1 (en) 2020-10-23
BR112020008122B1 (en) 2022-11-01
JP2021500380A (en) 2021-01-07

Similar Documents

Publication Publication Date Title
HUS2400003I1 (en) Compounds useful as kinase inhibitors
ZA201905811B (en) Novel inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
ZA201706710B (en) Heterocyclic compounds as lsd1 inhibitors
IL275207A (en) Oxy-fluoropiperidine derivative as kinase inhibitor
PT3371190T (en) Heterocyclic compounds as pi3k-gamma inhibitors
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
IL274036A (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
IL269063B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
ZA201804688B (en) New substituted cyanoindoline derivatives as nik inhibitors
ZA201907136B (en) Ip6k inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
IL271808A (en) New substituted azaindoline derivatives as nik inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors